日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study

瑞戈非尼联合伊立替康作为转移性胃食管腺癌二线治疗:PRODIGE 58-UCGI35-REGIRI Unicancer 随机 II 期研究结果

Samalin, E; Evesque, L; Turpin, A; De La Fouchardiere, C; Khemissa-Akouz, F; Bouché, O; Muller, M; Dermeche, S; Botsen, D; Tougeron, D; Zaanan, A; Ben Abdelghani, M; Guardiola, E; Dubreuil, O; Le Brun Ly, V; Hennequin, A; Watson, S; Sefrioui, D; Lecomte, T; De Sousa Carvalho, N; Hulin, A; Crapez, E; Castan, F; Senellart, H

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.

循环肿瘤DNA能够很好地预测晚期胃食管腺癌患者接受化疗联合免疫检查点抑制剂治疗的疗效

Tougeron David, Louvet Christophe, Desramé Jérôme, Evesque Ludovic, Angelergues Antoine, Carnot Aurélien, Breysacher Gilles, Zaanan Aziz, Etchepare Nicolas, Mabro May, Kaluzinski Laure, Petorin Caroline, Chibaudel Benoist, Aparicio Thomas, Bodere Anaïs, Rinaldi Yves, Le Malicot Karine, Emile Jean-François, Lepage Côme, Baures Aurélia, Djamai Hanane, Taly Valérie, Laurent-Puig Pierre

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

FOLFIRI联合度伐利尤单抗(加或不加曲美利木单抗)二线治疗晚期胃癌或胃食管交界处腺癌:PRODIGE 59-FFCD 1707-DURIGAST随机临床试验

Tougeron, David; Dahan, Laetitia; Evesque, Ludovic; Le Malicot, Karine; El Hajbi, Farid; Aparicio, Thomas; Bouché, Olivier; Bonichon Lamichhane, Nathalie; Chibaudel, Benoist; Angelergues, Antoine; Bodere, Anaïs; Phelip, Jean-Marc; Mabro, May; Kaluzinski, Laure; Petorin, Caroline; Breysacher, Gilles; Rinaldi, Yves; Zaanan, Aziz; Smith, Denis; Gouttebel, Marie-Claude; Perret, Clément; Etchepare, Nicolas; Emile, Jean-François; Sanfourche, Ivan; Di Fiore, Frédéric; Lepage, Côme; Artru, Pascal; Louvet, Christophe

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

阿维鲁单抗对比标准二线化疗治疗伴有微卫星不稳定性转移性结直肠癌患者:一项随机临床试验

Taïeb, Julien; Bouche, Olivier; André, Thierry; Le Malicot, Karine; Laurent-Puig, Pierre; Bez, Jérémie; Toullec, Clémence; Borg, Christophe; Randrian, Violaine; Evesque, Ludovic; Corbinais, Stéphane; Perrier, Hervé; Buecher, Bruno; Di Fiore, Frederic; Gallois, Claire; Emile, Jean Francois; Lepage, Côme; Elhajbi, Farid; Tougeron, David

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models

系统性给药的去毒 TLR4 激动剂在临床前模型中表现出强大的抗肿瘤活性和可接受的耐受性

Kamel Chettab, Chantel Fitzsimmons, Alexey Novikov, Morgane Denis, Capucine Phelip, Doriane Mathé, Pierre Antoine Choffour, Sabine Beaumel, Eric Fourmaux, Patrick Norca, David Kryza, Anne Evesque, Lars Petter Jordheim, Emeline Perrial, Eva-Laure Matera, Martine Caroff, Jerome Kerzerho, Charles Dumon

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models

经全身给药的脱毒TLR4激动剂在临床前模型中显示出强大的抗肿瘤活性和可接受的耐受性。

Kamel Chettab,Chantel Fitzsimmons,Alexey Novikov,Morgane Denis,Capucine Phelip,Doriane Mathé,Pierre Antoine Choffour,Sabine Beaumel,Eric Fourmaux,Patrick Norca,David Kryza,Anne Evesque,Lars Petter Jordheim,Emeline Perrial,Eva-Laure Matera,Martine Caroff,Jerome Kerzerho,Charles Dumontet

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

基于血液的RNA特征在转移性胰腺腺癌吉西他滨治疗中的应用性能

Piquemal, David; Bruno, Roman; Bournet, Barbara; Ghiringhelli, Francois; Noguier, Florian; Canivet, Cindy; Bertaut, Aurélie; Pierrat, Fabien; Evesque, Ludovic; Gamez, Amelia; Cros, Jerome; Rederstorff, Emilie; Petit, Erwan; Adnet, Johan; Saint, Angélique; Drouillard, Antoine; Kempf, Emmanuelle; Soularue, Emilie; Vincent, Julie; Baumgaertner, Isabelle; Hennequin, Audrey; Tournigand, Christophe; Lopez Trabada Ataz, Daniel; Bengrine, Leila; Lepage, Come; Manfredi, Sylvain; Afchain, Pauline; Trouilloud, Isabelle; Gagnaire, Alice; LoConte, Noelle K; Bachet, Jean-Baptiste

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial

FOLFIRINOX方案与吉西他滨方案作为胰腺癌辅助治疗的五年疗效:一项随机临床试验

Conroy, Thierry; Castan, Florence; Lopez, Anthony; Turpin, Anthony; Ben Abdelghani, Meher; Wei, Alice C; Mitry, Emmanuel; Biagi, James J; Evesque, Ludovic; Artru, Pascal; Lecomte, Thierry; Assenat, Eric; Bauguion, Lucile; Ychou, Marc; Bouché, Olivier; Monard, Laure; Lambert, Aurélien; Hammel, Pascal

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

一项针对接受铂类化疗后病情进展的肛管鳞状细胞癌患者的 retifanlimab (INCMGA00012) II 期研究 (POD1UM-202)

Rao, S; Anandappa, G; Capdevila, J; Dahan, L; Evesque, L; Kim, S; Saunders, M P; Gilbert, D C; Jensen, L H; Samalin, E; Spindler, K-L; Tamberi, S; Demols, A; Guren, M G; Arnold, D; Fakih, M; Kayyal, T; Cornfeld, M; Tian, C; Catlett, M; Smith, M; Spano, J-P

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

II期INTERACT-ION研究:伊扎贝利单抗(BI 754091)联合mDCF(多西他赛、顺铂和5-氟尿嘧啶)化疗后序贯放化疗治疗III期肛门鳞状细胞癌患者

Kim, Stefano; Boustani, Jihane; Vernerey, Dewi; Vendrely, Véronique; Evesque, Ludovic; Francois, Eric; Quero, Laurent; Ghiringhelli, Francois; de la Fouchardière, Christelle; Dahan, Laëtitia; Bouché, Oliver; Chibaudel, Benoist; Hajbi, Farid El; Vernet, Chloé; Rebucci-Peixoto, Magali; Feuersinger, Alexandra; Maritaz, Christophe; Borg, Christophe